All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ST266
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ST266
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Walter Reed Army Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 01, 2021
Details:
The TBI models will utilize targeted intranasal nose-to-brain administration of ST266. The ultimate goals are to advance ST266 into human clinical trials of targeted intranasal administration for TBI.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Mosedipimod
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: EC-18
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: NASA
Deal Size: $0.1 million Upfront Cash: Undisclosed
Deal Type: Funding January 26, 2021
Details:
NASA’s Human Research Program has awarded $150K in grant funding to conduct research on its lead compound EC-18, and how it impacts astronaut health and performance during future long-duration missions beyond low-Earth orbit.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tipelukast
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: MN-001
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: National Institute of General Medical Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
The study sought to examine the pathogenic role of phosphodiesterase 4 (PDE4) in hepatic stellate cell (HSC) activation and TGFβ1 (transforming growth factor beta 1) signaling. TGFβ1 induced HSC activation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BP-C2
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: BP-C2
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2020
Details:
BP-C2 reduces mortality when administered 24 hours post-exposure in a murine model of severe, radiation-induced gastrointestinal acute radiation syndrome (GI-ARS).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CX717
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: CX717
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
Details:
Studies describes the ability of CX717, one of the Company’s lead ampakines, to improve motor nerve function in an animal
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
